Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00147758 · ClinicalTrials.gov registry record · Phase 3
WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT00147758 is a Phase 3 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 400 participants.
The verdict
NCT00147758, a Phase 3 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
The purpose of the study is to see how safe and effective and tolerable the use of colesevelam hydrochloride is for type 2 diabetes when added to sulfonylurea alone or in combination with other anti-diabetic drugs.
Interventions
- DRUG Colesevelam hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2004-06 |
| Est. Completion | 2006-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00147758
The ClinicalTrials.gov registry entry for NCT00147758 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Colesevelam hydrochloride is the first listed.
NCT00147758 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00147758 about?
NCT00147758 is a clinical study titled "WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes". The purpose of the study is to see how safe and effective and tolerable the use of colesevelam hydrochloride is for type 2 diabetes when added to sulfonylurea alone or in combination with other anti-diabetic drugs.
What is the current status of trial NCT00147758?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2004-06. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00147758?
The interventions under investigation include: Colesevelam hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00147758?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.